Ocuphire Pharma Results

Topical Eyedrops in Clinical Development for DR/DME Inflammation MOAS in Phase 2 with Novel Eyedrops Company Drug Oculis OCS-01 OCUTERRA THERAPEUTICS OTT 166 Ocuphire Company websites; www.clinicaltrials.gov PHARMA Target/MOA Steroid Integrin inhibitor Indication DME DR Route of Administration Eyedrop Eyedrop ✓ Completed Phase 1 Phase 2 Phase 3 Commercial ✓ ✓ Ongoing X Discontinued or Failed study 27

View entire presentation